INC.

Intrinsic Therapeutics, Inc. Announces Positive Coverage Policy by Cigna Healthcare for Barricaid Bone-Anchored Annular Closure Device

by

BOSTON, June 21, 2023 /PRNewswire/ — Intrinsic Therapeutics, Inc., a medical device company focused on preventing reherniation and reoperation following lumbar discectomy, announced today that Cigna Healthcare has issued a positive coverage policy for the Barricaid® Bone-Anchored Annular Closure device. Cigna Healthcare represents one of the five largest commercial payors in the US, with an estimated … Read more

Aethlon Medical Announces Investigation of the Hemopurifier® for Use in Organ Transplantation

by

Research to Confirm the Hemopurifier’s Ability to Remove Harmful Viruses and Exosomes From Harvested Organs SAN DIEGO, June 21, 2023 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is investigating the use of its Hemopurifier® in the … Read more

Cosmetic Implants Market to be Worth $21.2 Billion by 2030: Grand View Research, Inc.

by

SAN FRANCISCO, June 21, 2023 /PRNewswire/ — The global cosmetic implants market size is expected to reach USD 21.2 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.8% from 2023 to 2030. Increasing demand for aesthetic procedures coupled with rising expenditure … Read more

Interius BioTherapeutics Highlights Strong Preclinical Data Supporting In Vivo Chimeric Antigen Receptor (CAR) Vector Evaluation in Clinic

by

Lead candidate demonstrates specificity, biologic activity and a favorable safety profile in extensive mouse and non-human primate models Upcoming company presentations at Cellicon Valley ’23 and In Vivo Engineering of Therapeutic Cells Summit PHILADELPHIA, June 21, 2023 /PRNewswire/ — Interius BioTherapeutics, a leading developer of in vivo cell-specific genetic medicine therapeutics, today announced the presentation of compelling … Read more

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis

by

VYVGART® Hytrulo is first FDA-approved subcutaneous (SC) injectable for generalized myasthenia gravis (gMG) SAN DIEGO, June 20, 2023 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that argenx received U.S. Food and Drug Administration (FDA) approval for VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection with ENHANZE® for subcutaneous (SC) use for the treatment … Read more

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

by

SAN DIEGO, June 20, 2023 /PRNewswire/ — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that on June 20, 2023, non-qualified stock option awards to purchase an aggregate of 40,032 shares of its common stock were granted to one new … Read more

IBC Launches Full Range of Best-in-Class Molecular Recognition Technology™ (MRT™) Flowsheets for Highly Selective Separations of Key Radionuclides and Preparation of Novel Chelating Agents for Radionuclide Incorporation into Radiopharmaceuticals USA – English India – English

by

Development of multiple anticancer drugs with radioisotopes is in progress Lu-177, Y-90, Cu-67, Ra-223, Ac-225, Pb-212 and At-211 have licensed products or are in clinical trials IBC’s state-of-the-art MRT™ separation and chelation technologies facilitate production of radiopharmaceuticals based on these and other medical radioisotopes Radioisotopes are separated at up to 99.99% purity and 99.9+% recovery … Read more

Veravas Launches Groundbreaking VeraBIND Technology for Ultra-Sensitive Assays and Matrix Free Sample Analysis

by

Revolutionary bead-based technology enables reliable biomarker detection in challenging samples, transforming clinical diagnostic performance and research workflows AUSTIN, Texas, June 20, 2023 /PRNewswire/ — Today, Veravas, a leading innovator in clinical diagnostics, announced the launch of its groundbreaking VeraBIND™ (Biomarker Isolation and N-richment for Detection) technology. With millions of assays conducted daily in clinical laboratories … Read more

Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer

by

NEW YORK, June 20, 2023 /PRNewswire/ — Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr.  Vojislav “Vojo” Vukovic as its new Chief Medical Officer (CMO). Dr. Vukovic is an experienced … Read more

Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

by

–  First FDA Breakthrough Therapy Designation granted for AdenoVerse immunotherapy platform; designation prioritizes PRGN-2012 as a potential treatment for RRP ––  Designation based on positive Phase 1 clinical data that showed 50% of patients were “surgery-free” (Complete Response) after PRGN-2012 treatment with a minimum follow up of 12 months post-treatment – GERMANTOWN, Md. , June 20, … Read more